A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
暂无分享,去创建一个
C. Pui | R. Ribeiro | J. Rubnitz | S. Pounds | N. Lacayo | H. Inaba | B. Degar | W. Leung | Huiyun Wu | B. Triplett | W. Janssen | R. Nguyen | D. Schiff | K. Heym | Teresa Bell | Barbara Rooney | David L Cullins
[1] H. Ljunggren,et al. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML , 2018, Clinical Cancer Research.
[2] K. Rezvani,et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.
[3] T. Waldmann,et al. A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells , 2015 .
[4] C. Pui,et al. Natural killer cell therapy in children with relapsed leukemia , 2015, Pediatric blood & cancer.
[5] M. Carroll,et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia , 2015, Leukemia.
[6] S. Pittaluga,et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. , 2015, Blood.
[7] S. Raimondi,et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Baccarani,et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.
[9] Elaine Coustan-Smith,et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.
[10] C. Pui,et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Campana,et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.
[12] M. Martinetti,et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. , 2009, Blood.
[13] D. Tough,et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection , 2007, Immunology.
[14] M. Martelli,et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.
[15] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[16] C. N. Coleman,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[17] M. Caligiuri,et al. What does it take to make a natural killer? , 2003, Nature Reviews Immunology.
[18] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[19] A. Criel,et al. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing , 2001, Bone Marrow Transplantation.
[20] K. Nakachi,et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.
[21] J. Klein,et al. IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.
[22] Dean Anthony Lee,et al. Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21. , 2016, Methods in molecular biology.
[23] R. Kapp,et al. Food, Drug, and Cosmetic Act , 2005 .
[24] Peter Parham,et al. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. , 2002, Annual review of immunology.